Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis
نویسندگان
چکیده
منابع مشابه
Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
Objective The primary objective of this study was to document the hospitalization rate due to respiratory syncytial virus (RSV) and compliance with palivizumab use in preterm infants receiving palivizumab immunoprophylaxis during 2009-2012 RSV seasons. Design This is a descriptive single-center cohort study. Infants who were ≤35-week gestational age were eligible for enrollment if they receiv...
متن کاملPalivizumab for respiratory syncytial virus prophylaxis.
Palivizumab, a humanized monoclonal antibody, has been approved by the FDA to prevent severe lower respiratory tract infections caused by RSV in high-risk patients. Prophylaxis of RSV infections with palivizumab requires monthly injections (15 mg/kg) during the RSV season. In the IMpact-RSV study, hospitalizations resulting from RSV decreased by 55% in the palivizumab treatment group. Palivizum...
متن کاملPalivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
BACKGROUND Prophylactic therapy with palivizumab, a humanized monoclonal antibody, has been shown to reduce the number of respiratory syncytial virus (RSV)-related hospitalizations in preterm infants. The cost-effectiveness of this therapy has not been evaluated from the provider's perspective using cost data. OBJECTIVES The objectives of this study were to determine the cost per RSV infectio...
متن کاملTreatment of respiratory syncytial virus with palivizumab: a systematic review.
BACKGROUND Palivizumab has proven efficacy for prophylaxis of respiratory syncytial virus (RSV) in infants with prematurity or congenital heart disease. Despite a paucity of data, palivizumab is sometimes used to prevent progression when high-risk patients present with upper respiratory tract infection (URTI) due to RSV, or as therapy when any patients present with severe lower respiratory trac...
متن کاملEfficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
IMPORTANCE Infection with the respiratory syncytial virus (RSV) is the leading cause of hospitalizations in children, accounting for more than 90,000 hospitalizations every year in the United States. For children who are at risk for severe RSV infections, the American Academy of Pediatrics recommends immunoprophylaxis with a series of up to 5 injections of the antibody palivizumab administered ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Pediatrics
سال: 2019
ISSN: 0022-3476
DOI: 10.1016/j.jpeds.2019.06.058